Moderna Expands Horizons With Vertex and Chiesi Deals
Pacts Come Ahead Of R&D Day
The world is waiting for Moderna’s COVID-19 vaccine results, but meanwhile the company is exploring new avenues to secure long-term growth
You may also be interested in...
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.
After a long-standing row with payer NHS England, the rapid market access deal will help Vertex move into growth phase.
Timing means full EU approval could coincide with US FDA authorization later this year.